Hereditary Angioedema Market Report 2025

The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to factors such as the rising prevalence of hereditary angioedema, increased investment in research and development, a higher number of drug approvals, growing product approvals, and an increase in disposable income.

The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of rare diseases, rising medical expenditure, greater support from non-profit organizations, heightened awareness of hereditary angioedema, and a growing focus on early diagnosis. Key trends in the forecast period include technological innovations, the development of new therapies, the introduction of new drugs, advancements in diagnostic tools, and progress in genetic testing.

The increasing prevalence of rare diseases is expected to drive the growth of the hereditary angioedema (HAE) market in the coming years. Rare diseases, often referred to as orphan diseases, affect a small segment of the population, and their rising prevalence can be attributed to factors such as advancements in medical research, demographic shifts, and environmental changes. Hereditary angioedema, a notable rare disease, underscores the need for specialized treatments and awareness due to its potentially life-threatening swelling episodes. Its genetic nature and rarity make early diagnosis and targeted therapies crucial for better patient outcomes. According to Rare Disease Advisor, as of June 2022, HAE affects around 1 in 50,000 individuals, with prevalence estimates ranging from 1 in 10,000 to 1 in 150,000. In the U.S., HAE episodes account for approximately 15,000 to 30,000 emergency room visits annually. As a result, the growing number of rare disease cases is fueling the expansion of the hereditary angioedema market.

Leading companies in the hereditary angioedema market are working on developing groundbreaking products, such as oral plasma kallikrein inhibitors, to offer more convenient and effective on-demand treatment solutions for patients. These inhibitors work by blocking plasma kallikrein to prevent excessive production of bradykinin, which is central to treating hereditary angioedema. For example, in September 2024, KalVista Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the FDA had accepted its new drug application (NDA) for sebetralstat, an oral plasma kallikrein inhibitor. Sebetralstat is designed for on-demand treatment of hereditary angioedema attacks in both adult and pediatric patients aged 12 and older. The NDA acceptance marks an important step towards the drug's potential approval and commercialization.

In July 2023, BioCryst Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, partnered with Er-Kim Pharmaceuticals to commercialize ORLADEYO (berotralstat) in Turkey. This collaboration aims to improve access to ORLADEYO for hereditary angioedema patients in Turkey while expanding BioCryst's presence in the global rare disease market. Er-Kim Pharmaceuticals is a Turkish company dedicated to the development, manufacturing, and marketing of high-quality medicines across various therapeutic areas.

Major players in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., and Lev Pharmaceuticals Inc.

North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary angioedema report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hereditary angioedema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hereditary angioedema (HAE) is a rare genetic condition marked by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways, resulting from a deficiency or dysfunction of C1 esterase inhibitor. This disorder is caused by genetic mutations affecting the complement system, leading to an overproduction of bradykinin. HAE can be life-threatening if it causes airway swelling, which requires immediate treatment with C1 inhibitor replacement or therapies targeting bradykinin.

The primary types of hereditary angioedema are type I and type II. Type I HAE, the most common form, is caused by a deficiency of C1 esterase inhibitor (C1-INH), resulting in uncontrolled bradykinin production and repeated episodes of swelling. Treatment for HAE is generally categorized into prophylactic and on-demand approaches, utilizing various drug classes such as C1 esterase inhibitors, bradykinin receptor antagonists, kallikrein inhibitors, and others. These treatments are delivered through different methods, including subcutaneous, intravenous, and oral routes, and are available via hospital pharmacies, retail pharmacies, and online pharmacies.

The hereditary angioedema market research report is one of a series of new reports that provides hereditary angioedema market statistics, including the hereditary angioedema industry global market size, regional shares, competitors with the hereditary angioedema market share, detailed hereditary angioedema market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema industry. This hereditary angioedema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hereditary angioedema market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, acute attack management, and long-term prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema market also includes sales of plasma-derived products, biologics, and therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.